Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Daniel Nguyen

Clinical Cardiac Electrophysiology Orlando, FL Medical Doctor

NPI 1467794560 CMS profile 7180029

1222 S Orange Ave Fl 3, Orlando, FL 32806

Open in the dashboard

General payments

$47,296

255 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Daniel Nguyen of Orlando, FL is reported in the CMS Open Payments database as having received $47,296 across 255 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 75th percentile of Clinical Cardiac Electrophysiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $6,157 70
2024 General $1,535 38
2023 General $1,459 35
2022 General $2,244 16
2021 General $3,936 30
2020 General $15,566 28
2019 General $16,400 38

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Daniel Nguyen
  • Clinical Cardiac Electrophysiology median
  • Middle half of Clinical Cardiac Electrophysiology
  • National median

In program year 2025, general payments to Daniel Nguyen were reported at $6,157. Among 3,064 Clinical Cardiac Electrophysiology profiles paid that year, the median was $2,462 and the middle half received between $733 and $7,710.

Show as a table
Year Daniel Nguyen Clinical Cardiac Electrophysiology median Middle half National median
2019 $16,400 $2,361 $585–$8,260 $163
2020 $15,566 $993 $247–$4,351 $114
2021 $3,936 $1,185 $326–$4,739 $132
2022 $2,244 $2,073 $554–$6,789 $149
2023 $1,459 $2,568 $759–$8,159 $160
2024 $1,535 $2,557 $703–$7,403 $164
2025 $6,157 $2,462 $733–$7,710 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic Vascular, Inc. $16,812 8 payments
  2. Boston Scientific Corporation $13,609 43 payments
  3. Abbott Laboratories $7,859 52 payments
  4. AltaThera Pharmaceuticals LLC $2,253 3 payments
  5. Biotronik Inc. $2,074 15 payments
  6. Medtronic, Inc. $1,867 35 payments
  7. Biosense Webster, Inc. $918 21 payments
  8. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $342 22 payments
  9. Atricure, Inc. $252 5 payments
  10. Cardiva Medical, Inc. $185 4 payments
  11. Other $1,127 47 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Grant $31,212 7 payments
  2. Food and Beverage $9,381 225 payments
  3. Travel and Lodging $4,185 14 payments
  4. Consulting Fee $1,875 1 payment
  5. Education $643 8 payments
Products named General payments · program years 2019–2025
  1. GENERAL BRADY $5,000 1 payment
  2. GENERAL - BRADY $5,000 1 payment
  3. General Therapies $2,422 10 payments
  4. Sotalol Hydrochloride $2,253 3 payments
  5. Acticor 7 VR-T DX $1,715 4 payments
  6. BioMonitor $1,675 8 payments
  7. Solia $1,660 7 payments
  8. Rivacor 7 DR-T $1,593 2 payments
  9. TactiCath SE $1,515 1 payment
  10. Assurity Pacemaker $1,515 1 payment
  11. Other $11,868 252 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 24 drugs

Part D claims

1,181

Median for Clinical Cardiac Electrophysiology: 1,090

Drug cost

$437,267

Median for Clinical Cardiac Electrophysiology: $354,841

Branded share of claims

40.1%

Median for Clinical Cardiac Electrophysiology: 38.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 253 $292,474
Xarelto Rivaroxaban Brand 63 $79,220
Entresto Sacubitril/Valsartan Brand 11 $20,106
Multaq Dronedarone Hcl Brand 17 $18,668
Dofetilide Generic 44 $10,016
Amiodarone Hcl Generic 151 $4,204
Metoprolol Succinate Generic 155 $2,599
Mexiletine Hcl Generic 18 $2,282
Flecainide Acetate Generic 29 $1,507
Sotalol Sotalol Hcl Brand 55 $1,362

The 10 drugs with the highest cost, of 24 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,573 Part D prescribers listed as Clinical Cardiac Electrophysiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 88 billing codes

Paid by Medicare

$219,731

Medicare's payments for the services billed

Medicare patients

908

Average age 78

Services billed

3,216

398 women, 510 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 66%
Atrial fibrillation 65%
Heart failure 54%
Chronic kidney disease 51%
Arthritis 49%
Diabetes 41%
Depression 28%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

2 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VYNDAQEL
$15 — —
CAMZYOS
$15 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

255 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Clinical Cardiac Electrophysiology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record